0001264124-12-000099.txt : 20120307 0001264124-12-000099.hdr.sgml : 20120307 20120307180417 ACCESSION NUMBER: 0001264124-12-000099 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120306 FILED AS OF DATE: 20120307 DATE AS OF CHANGE: 20120307 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KOLTERMAN ORVILLE G CENTRAL INDEX KEY: 0001236394 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19700 FILM NUMBER: 12675334 MAIL ADDRESS: STREET 1: AMYLIN PHARMACEUTICALS INC STREET 2: 9360 TOWNE CENTRE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMYLIN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000881464 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330266089 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6195522200 MAIL ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0304 4 2012-03-06 0 0000881464 AMYLIN PHARMACEUTICALS INC AMLN 0001236394 KOLTERMAN ORVILLE G 9360 TOWNE CENTRE DR SAN DIEGO CA 92121 0 1 0 1 SVP, Chief Medical Officer SVP, Chief Medical Officer Common Stock 2012-03-06 4 A 0 10000 0 A 184276.9 D Common Stock 2012-03-06 4 A 0 1529.3 0 A 7974.4 I by ESOP Common Stock 12767.3 I Indirect-401k Incentive Stock Option (right to buy) 16.02 2012-03-06 4 A 0 7901 0 A 2019-03-06 Common Stock 7901 7901 D Non-Qualified Stock Option (right to buy) 16.02 2012-03-06 4 A 0 42099 0 A 2019-03-06 Common Stock 42099 42099 D Represents a restricted stock unit award that vests in three equal annual installments from the date of grant. Restricted stock units are generally settled in shares of common stock of the company on the vesting date. These shares fully vest four years from the date of the reporting person's participation in the ESOP in four equal annual installments and are generally distributed upon termination of employment. 25% of shares vest one year from the date of grant and the remainder vest in three equal annual installments becoming fully vested four years from the date of grant. By: /s/ James R. Oehler, Attorney-in-Fact For: Orville G. Kolterman 2012-03-07